A Phase 2 interventional study of olaparib in Ovarian, Breast and Prostate, sponsored by AstraZeneca. Completed at 14 sites in 6 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-08-13.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To assess the efficacy of oral olaparib in patients with advanced cancer who have a confirmed genetic BRCA1 and/or BRCA2 mutation, by assessment of tumour response
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose recommended by Investigator. Full dose: 300 mg twice daily (bid) or Reduced doses: 200 mg twice daily (bid) or 100 mg twice daily (bid). The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions.
Drug: olaparib
Tablets Oral BID
Also known as: Lynparza
Tumour Response Rate
Tumour response rate is the proportion of patients who experienced complete or partial response at least once during the assessment period, according to the definitions of Response Evaluation Criteria In Solid Tumours (RECIST version 1.1).
Time frame: Tumour assessments carried out at baseline ie 28 days before first study drug dose and then every 8 weeks up to 6 months after starting study treatment, then every 12 weeks until objective disease progression, assessed maximum up to 29 months
Objective Response Rate
Objective response rate is the proportion of patients with at least one measurable lesion at baseline, who experienced complete or partial response at least once during the assessment period, according to the definitions of Response Evaluation Criteria In Solid Tumours (RECIST version 1.1).
Time frame: Tumour assessments carried out at baseline ie 28 days before first study drug dose and then every 8 weeks up to 6 months after starting study treatment, then every 12 weeks until objective disease progression, assessed maximum up to 29 months
Progression Free Survival
Progression free survival is defined as the duration from first dose till objective progression or death. In absence of progression or death, the time is calculated from first dose till last evaluable scanning visit.
Time frame: Tumour assessments are carried out at baseline ie 28 days before first study drug dose and then every 8 weeks up to 6 months after starting study treatment, then every 12 weeks until objective disease progression, assessed maximum up to 29 months
Overall Survival
Overall survival is defined as the duration from first dose till death. In absence of death, the time is calculated from first dose till the date subject last known to be alive.
Time frame: Survival follow-up from first dose till death of the patient or till end of study in absence of death, assessed maximum up to 29 months
Overall Survival Rate at 12 Months
Overall survival rate at 12 months is defined as the proportion of patients who are alive 12 months after date of first dose
Time frame: Survival follow-up from first dose till death of the patient or till end of study in absence of death, assessed maximum up to 29 months
Duration of Response
Duration of response is calculated from the date of first documented response (complete or partial) until date of documented progression (as defined by RECIST 1.1) or death (by any cause) in the absence of disease progression.
Time frame: From onset of first occurrence of complete or partial response till documented progression or death by any cause in the absence of progression, assessed maximum up to 29 months
Disease Control Rate at Week 16
Disease control rate is the proportion of patients with best response of complete or partial response or stable disease according to definitions of Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) till week 16.
Time frame: Tumour assessments carried out at baseline ie 28 days before first study drug dose and then at week 8 and week 16
This study was conducted at 13 sites across Israel, Germany, Spain, Australia, USA, Sweden. Enrolment started in Feb 2010 and was completed in Jul 2012. In total, 298 patients had received treatment (olaparib).
| Milestone | Breast Cancer | Ovarian Cancer | Pancreatic Cancer | Prostate Cancer | Other Cancers |
|---|---|---|---|---|---|
| Started | 62 | 193 | 23 | 8 | 12 |
| Completed | 4 | 25 | 2 | 1 | 1 |
| Not completed | 58 | 168 | 21 | 7 | 11 |
| Withdrew: Death | 41 | 103 | 18 | 5 | 8 |
| Withdrew: Patients reached data cut-off | 12 | 53 | 2 | 2 | 3 |
| Withdrew: Withdrawal by subject | 4 | 11 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 |
Tumour response rate is the proportion of patients who experienced complete or partial response at least once during the assessment period, according to the definitions of Response Evaluation Criteria In Solid Tumours (RECIST version 1.1).
| Percentage of participants | Breast Cancer | Ovarian Cancer | Pancreatic Cancer | Prostate Cancer | Other Cancers | All Patients |
|---|---|---|---|---|---|---|
| Tumour Response Rate | 12.9 (5.74 to 23.85) | 31.1 (24.64 to 38.13) | 21.7 (7.46 to 43.7) | 50 (15.7 to 84.3) | 8.3 (0.21 to 38.48) | 26.2 (21.27 to 31.55) |
Objective response rate is the proportion of patients with at least one measurable lesion at baseline, who experienced complete or partial response at least once during the assessment period, according to the definitions of Response Evaluation Criteria In Solid Tumours (RECIST version 1.1).
| Percentage of participants | Breast Cancer | Ovarian Cancer | Pancreatic Cancer | Prostate Cancer | Other Cancers | All Patients |
|---|---|---|---|---|---|---|
| Objective Response Rate | 13.8 (6.15 to 25.38) | 35.9 (28.66 to 43.7) | 21.7 (7.46 to 43.7) | 57.1 (18.41 to 90.1) | 9.1 (0.23 to 41.28) | 29.3 (23.92 to 35.19) |
Progression free survival is defined as the duration from first dose till objective progression or death. In absence of progression or death, the time is calculated from first dose till last evaluable scanning visit.
| months | Breast Cancer | Ovarian Cancer | Pancreatic Cancer | Prostate Cancer |
|---|---|---|---|---|
| Progression Free Survival | 3.68 (1.76 to 7.52) | 7.03 (3.65 to 11.24) | 4.55 (1.81 to 8.21) | 7.15 (2.63 to 17.45) |
Overall survival is defined as the duration from first dose till death. In absence of death, the time is calculated from first dose till the date subject last known to be alive.
| months | Breast Cancer | Ovarian Cancer | Pancreatic Cancer | Prostate Cancer |
|---|---|---|---|---|
| Overall Survival | 11.01 (5.68 to 24.18) | 16.62 (9.43 to NA) | 9.81 (3.84 to 16.62) | 18.38 (6.24 to 25.46) |
Overall survival rate at 12 months is defined as the proportion of patients who are alive 12 months after date of first dose
| Percentage of participants | Breast Cancer | Ovarian Cancer | Pancreatic Cancer | Prostate Cancer |
|---|---|---|---|---|
| Overall Survival Rate at 12 Months | 44.7 (5.68 to 24.18) | 64.4 (9.43 to NA) | 40.9 (3.84 to 16.62) | 50 (6.24 to 25.46) |
Duration of response is calculated from the date of first documented response (complete or partial) until date of documented progression (as defined by RECIST 1.1) or death (by any cause) in the absence of disease progression.
| days | Breast Cancer | Ovarian Cancer | Pancreatic Cancer | Prostate Cancer | Other Cancers | All Patients |
|---|---|---|---|---|---|---|
| Duration of Response | 204 (149.5 to 405) | 225 (143 to 410) | 134 (131 to 141) | 326.5 (164 to 476) | 165 (165 to 165) | 208 (134 to 410) |
Disease control rate is the proportion of patients with best response of complete or partial response or stable disease according to definitions of Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) till week 16.
| Percentage of participants | Breast Cancer | Ovarian Cancer | Pancreatic Cancer | Prostate Cancer | Other Cancers | All Patients |
|---|---|---|---|---|---|---|
| Disease Control Rate at Week 16 | 37.1 (25.16 to 50.31) | 58 (50.73 to 65.08) | 47.8 (26.82 to 69.41) | 62.5 (24.49 to 91.48) | 33.3 (9.92 to 65.11) | 52 (46.18 to 57.81) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OLAPARIB | — | 90/298 (30.2%) | 290/298 (97.3%) |
| Event | OLAPARIB |
|---|---|
| ANAEMIABlood and lymphatic system disorders | 13/298 |
| ABDOMINAL PAINGastrointestinal disorders | 11/298 |
| INTESTINAL OBSTRUCTIONGastrointestinal disorders | 7/298 |
| SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders | 7/298 |
| VOMITINGGastrointestinal disorders | 5/298 |
| PNEUMONIAInfections and infestations | 4/298 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 4/298 |
| PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders | 4/298 |
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 4/298 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 3/298 |
| Event | OLAPARIB |
|---|---|
| NAUSEAGastrointestinal disorders | 176/298 |
| FATIGUEGeneral disorders | 176/298 |
| VOMITINGGastrointestinal disorders | 109/298 |
| ANAEMIABlood and lymphatic system disorders | 90/298 |
| DIARRHOEAGastrointestinal disorders | 81/298 |
| ABDOMINAL PAINGastrointestinal disorders | 66/298 |
| DECREASED APPETITEMetabolism and nutrition disorders | 62/298 |
| DYSPEPSIAGastrointestinal disorders | 52/298 |
| HEADACHENervous system disorders | 48/298 |
| DYSGEUSIANervous system disorders | 47/298 |
| Age, Continuous(years) | Breast Cancer | Ovarian Cancer | Pancreatic Cancer | Prostate Cancer | Other Cancers | Total |
|---|---|---|---|---|---|---|
| Mean | 47.6 ± 9.69 | 57.2 ± 9.28 | 57.1 ± 7.99 | 66.6 ± 9.86 | 54.9 ± 12.38 | 55.3 ± 10.3 |
| Age, Customized(Participants) | Breast Cancer | Ovarian Cancer | Pancreatic Cancer | Prostate Cancer | Other Cancers | Total |
|---|---|---|---|---|---|---|
| < 50 years | 33 | 40 | 6 | 0 | 4 | 83 |
| >=50 to <65 years | 28 | 117 | 14 | 3 | 5 | 167 |
| >= 65 years | 1 | 36 | 3 | 5 | 3 | 48 |
| Sex: Female, Male(Participants) | Breast Cancer | Ovarian Cancer | Pancreatic Cancer | Prostate Cancer | Other Cancers | Total |
|---|---|---|---|---|---|---|
| Female | 61 | 193 | 10 | 0 | 8 | 272 |
| Male | 1 | 0 | 13 | 8 | 4 | 26 |
| Race/Ethnicity, Customized(Participants) | Breast Cancer | Ovarian Cancer | Pancreatic Cancer | Prostate Cancer | Other Cancers | Total |
|---|---|---|---|---|---|---|
| White | 60 | 183 | 21 | 8 | 11 | 283 |
| Black or African American | 0 | 1 | 1 | 0 | 0 | 2 |
| Asian | 1 | 8 | 1 | 0 | 1 | 11 |
| Other | 1 | 1 | 0 | 0 | 0 | 2 |
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Feb 2010 to primary completion in Jul 2012, 29 months.
Results were first posted in May 2015, 2 years 9 months after primary completion. A results delay was requested in May 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib